Amgen goes back to Rhode Island to build its first next-gen manufacturing site in the US
In a bid to lead the way in developing a new generation of more efficient biologics manufacturing facilities, Amgen $AMGN is investing $160 million in a new plant to be constructed on its Rhode Island base.
The pharma giant $AMGN — headquartered in Thousand Oaks, CA — has had a long history with the 75-acre campus in West Greenwich, RI, since inheriting it in the Immunex acquisition in 2001. With the new operation, it plans to add around 150 manufacturing positions to the 625-strong team. The state government was happy to hear about that job creation, in addition to 200 temporary construction and validation jobs, and has promised $9.5 million in tax credits to move things along.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.